With significant experience in financial analysis at a biotech company, he's adept at creating detailed financial models using methods like Discounted Cash Flow (DCF), comparable company analyses, and precedent transaction multiples in the biotech and healthcare sectors. Farzan specializes in financial due diligence for buy-side and sell-side transactions, particularly for private equity clients, identifying synergies and cost-saving opportunities throughout the deal lifecycle. He has a proven track record in constructing synergy analyses by leveraging historical data to optimize post-integration efficiency.